详情

原文传递 Validating Conditionally Reprogrammed Cells to Advance Personalized Medicine for Prostate Cancer.

题名：	Validating Conditionally Reprogrammed Cells to Advance Personalized Medicine for Prostate Cancer.
作者：	Albanese, C.; Feldman, A.; Petricoin, E.
关键词：	Culture media, Databases, Gene expression, Personalized medicine, Peptide growth factors, Proteomics, Indicator dyes, Proteins, Tumor cell line, Cultured cells, Oncology, Cell line, Carcinoma, Genetics, Culture techniques, Cell physiological processes, Stem cells, Chemistry, Medical personnel, Health services
摘要：	With more than 26,000 deaths from prostate cancer (PCa) in the United States each year, a more comprehensive understanding of the pathobiology of PCa and the identification of markers to reliably predict aggressive disease, select targeted therapies and assess clinical outcome remain significant areas of unmet need. Unfortunately, primary tissue is limiting due to the focus on obtaining an accurate clinical diagnosis. And the available prostate cell lines for correlative analyses are suboptimal for many applications. A confounding problem is that long-termed culturing of prostate epithelial cells has not been previously possible without oncogenic transformation. We have developed a novel culture, termed conditionally reprogrammed cells, or CRCs, of both normal and cancerous prostate epithelial cells. The CRCs have been propagated in excess of 100 population doublings with no gross genetic changes (1). Importantly, and we have applied the CRC approach to successfully identify a drug that was used to effectively treat (>18 months as a stable disease) a patient who was in the terminal stages of respiratory papillomatosis (2), and our recent papers have used prostate CRCs for drug development(3,4) providing strong evidence of the fidelity of the method itself and its translational/clinical impact.
报告类型：	科技报告